Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Boundless Bio Inc (BOLD)

Boundless Bio Inc (BOLD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights GlobeNewswire - Fri May 8, 6:00AM CDT

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May...

BOLD : 1.4400 (-0.69%)
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting GlobeNewswire - Fri Apr 17, 3:49PM CDT

SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 1.4400 (-0.69%)
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 GlobeNewswire - Tue Mar 17, 3:52PM CDT

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 1.4400 (-0.69%)
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights GlobeNewswire - Mon Mar 9, 6:00AM CDT

KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1...

BOLD : 1.4400 (-0.69%)
Boundless Bio to Participate in the Leerink Global Healthcare Conference GlobeNewswire - Wed Mar 4, 6:00AM CST

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

BOLD : 1.4400 (-0.69%)
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 GlobeNewswire - Thu Feb 5, 6:00AM CST

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 1.4400 (-0.69%)
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway GlobeNewswire - Tue Jan 20, 6:00AM CST

BBI-940 IND accepted; initiation of first-in-human clinical trial on track  for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating...

BOLD : 1.4400 (-0.69%)
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Mon Nov 24, 2025

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 1.4400 (-0.69%)
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Wed Nov 5, 2025

 Enrollment ongoing in BBI-355 / BBI-825 combination arm of the POTENTIATE trial Investigational new drug submission for BBI-940 on track, with a first-in-human clinical trial expected to initiate...

BOLD : 1.4400 (-0.69%)
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire - Mon Oct 13, 2025

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio , (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to...

BOLD : 1.4400 (-0.69%)

Barchart Exclusives

Can November Soybeans Challenge Contract Highs? Strong Crush Demand and Seasonal Strength Say It's Possible Barchart - Sat May 23, 3:37PM CDT
November soybeans may be setting up one of the better seasonal opportunities in ag markets right now. Record crush demand, bullish technicals, and a weather market season are all lining up at the same time.MRCI research also shows Nov beans closed higher in this seasonal window 12 of the past 15 years, with 8 of those years seeing no daily closing drawdowns.That kind of historical consistency gets traders' attention! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.